

STUDY TITLE	TOMORROW (paediatric use Of Macitentan To delay disease pRogReasion on PAH Worldwide): A multicentre, open-label, randomized, event-driven study to assess efficacy, safety and pharmacokinetics of macitentan versus standard of care in children with pulmonary arterial hypertension
STUDY POPULATION	The purpose of the study is to establish the efficacy and safety of macitentan in children with PAH treated with a dispersible formulation using a clinical composite primary endpoint and targeting a similar exposure as seen in adults with macitentan 10 mg and eligible based on the research inclusion and exclusion criteria.
PRINCIPAL INVESTIGATOR	Dr. Geetha Kandavello, Senior Consultant Paediatric Cardiologist, PCHC Cardiology Dept, IJNSB
STUDY COORDINATOR	Noor Syamira Mokhtar Contact number : 03 – 2617 8200 Ext 3133
START DATE	7 July 2020
END DATE	1 June 2025